Janux stock plunges after hours following mCRPC trial data
Lenz Therapeutics NASDAQ:LENZ Chief Financial Officer Daniel R. Chevallard reported purchasing shares of common stock on November 7, 2025, in two transactions totaling $50,016. The price range for these purchases was between $22.71 and $22.7561. This insider buying comes as the stock has taken a significant hit, dropping over 22% in the past week according to InvestingPro data.
The first transaction involved the purchase of 20 shares of Lenz Therapeutics stock at $22.71 per share. The second transaction involved the purchase of 2,178 shares at $22.7561 per share. Following these transactions, Chevallard directly owns 5,386 shares of Lenz Therapeutics.The CFO’s purchase price is notably below the stock’s 52-week high of $50.40, though InvestingPro analysis suggests the stock may still be trading above its Fair Value despite the recent decline. The company, with a market capitalization of approximately $619 million, holds more cash than debt on its balance sheet but remains unprofitable over the last twelve months. InvestingPro offers additional insights with its comprehensive Pro Research Report, available for Lenz Therapeutics and 1,400+ other US equities.
In other recent news, LENZ Therapeutics announced its Q3 2025 earnings, revealing a substantial increase in operating expenses alongside a net loss per share. This financial report followed the launch of their new eye drop product, VIZ, which has shown promising market potential. Despite the successful product launch, investor sentiment was affected by the financial results. The company’s financial performance led to a notable decline in its stock price. Analysts have not yet provided any upgrades or downgrades following the earnings report. There are no new merger announcements or other major company developments at this time. Investors are closely monitoring the situation for any further updates from LENZ Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.